Results 21 to 30 of about 790 (114)

Comparative Analysis of Compendial Quality Requirements for Carvedilol Products

Регуляторные исследования и экспертиза лекарственных средств
INTRODUCTION. Carvedilol is a drug used to treat renovascular hypertension and cardiovascular diseases. A monograph for carvedilol drug substance has been included in the State Pharmacopeia of the Russian Federation (SP RF); however, quality requirements
A. I. Belanova, E. V. Lankina, A. A. Taranova   +2 more
doaj   +1 more source

Carvedilol versus propranolol in the prevention of variceal rebleeding in hepatosplenic schistosomiasis: Efficacy and safety

JGH Open, 2022
Background and Aim Beta blockers combined with endoscopic variceal band ligation (EVL) is the most effective means for the prevention of variceal rebleeding.
Chantelli Iamblaudiot Razafindrazoto, Lova Dany Ella Razafindrabekoto, Domoina Harivonjy Hasina Laingonirina, Raveloson Raveloson, Anjaramalala Sitraka Rasolonjatovo, Andry Lalaina Rinà Rakotozafindrabe, Tovo Harimanana Rabenjanahary, Soloniaina Hélio Razafimahefa, Rado Manitrala Ramanampamonjy   +8 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol

ESC Heart Failure
Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta‐blockers. Degenerative
Wei‐Chieh Lee, Yu‐Wen Lin, Jhih‐Yuan Shih, Zhih‐Cherng Chen, Nan‐Chun Wu, Wei‐Ting Chang   +5 more
doaj   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

HEART FAILURE, DIABETES, BETA-BLOCKERS AND RISK OF HYPOGLYCEMIA

Рациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate an influence of carvedilol on risk of hypoglycemia in patients with diabetes type 2 (D2) and chronic heart failure (CHF) treated with angiotensin converting enzyme (ACE) inhibitors.Material and methods. 13 patients (10 men, 3 women; aged
A. A. Aleksandrov, O. А. Shatskaya, S. S. Kuharenko, E. N. Drozdova, I. Z. Bondarenko, N. D. Tabidze, M. V. Shestakova   +6 more
doaj   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Carvedilol Confers Ferroptosis Resistance in HL-1 Cells by Upregulating GPX4, FTH1, and FTL1 and Inducing Metabolic Remodeling Under Hypoxia/Reoxygenation

Antioxidants
Hypoxia/reoxygenation (HR) often occurs under cardiac pathological conditions, and HR-induced oxidative stress usually leads to cardiomyocyte damage. Carvedilol, a non-selective β-blocker, is used clinically to treat cardiac ischemia diseases.
Yi-Chin Li, Mei-Ling Cheng
doaj   +1 more source

Jervell and Lange‐Nielsen Syndrome Related Clinical Genetics and Experimental Models

Pediatric Discovery, EarlyView.
ABSTRACT Jervell and Lange‐Nielsen syndrome (JLNS) is defined by electrocardiographic QT prolongation and sensorineural hearing loss, caused by homozygous or compound heterozygous variants in KCNQ1 and/or KCNE1. KCNQ1 encodes the alpha subunit Kv7.1 of the ion channels accountable for slow delayed rectifier potassium currents (IKs), whereas KCNE1 ...
Yafei Zhou, Christopher L.‐H. Huang, Ying Yang, Yanmin Zhang   +3 more
wiley   +1 more source

Carvedilol Prevents UV-Induced Immunosuppression and Skin Carcinogenesis through a Mechanism Independent of β-Blockade

JID Innovations
Exposure to UVR suppresses the immune system, which plays a primary role in skin cancer etiology. The β-blocker carvedilol prevents UV-induced skin cancer, but the mechanism is unknown. This study examined the effects of carvedilol and its enantiomers on
Ayaz Shahid, Fanglong Dong, Bradley T. Andresen, Ying Huang   +3 more
doaj   +1 more source